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Changes of lipidic storage, oxidative stress and mitochondrial dysfunction may be
involved in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Although
the knowledge of intracellular pathways has vastly expanded in recent years, the
role and mechanisms of circulating triggering factor(s) are debated. Thus, we
tested the hypothesis that factors circulating in the blood of NAFLD patients may
influence processes underlying the disease. Huh7.5 cells/primary human hepatocytes
were exposed to plasma from 12 NAFLD patients and 12 healthy subjects and
specific assays were performed to examine viability, H2O2 and mitochondrial reactive
oxygen species (ROS) release, mitochondrial membrane potential and triglycerides
content. The involvement of NLRP3 inflammasome and of signaling related to
peroxisome-proliferator-activating-ligand-receptor-γ (PPARγ), sterol-regulatory-element-
binding-protein-1c (SREBP-1c), nuclear-factor-kappa-light-chain-enhancer of activated
B cells (NF-kB), and NADPH oxidase 2 (NOX2) was evaluated by repeating the
experiments in the presence of NLRP3 inflammasome blocker, MCC950, and through
Western blot. The results obtained shown that plasma of NAFLD patients was able to
reduce cell viability and mitochondrial membrane potential by about 48 and 24% (p <
0.05), and to increase H2O2, mitochondrial ROS, and triglycerides content by about 42,
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19, and 16% (p < 0.05), respectively. An increased expression of SREBP-1c, PPARγ,
NF-kB and NOX2 of about 51, 121, 63, and 46%, respectively, was observed (p
< 0.05), as well. Those effects were reduced by the use of MCC950. Thus, in
hepatocytes, exposure to plasma from NAFLD patients induces a NAFLD-like phenotype
by interference with NLRP3-inflammasome pathways and the activation of intracellular
signaling related to SREBP-1c, PPARγ, NF-kB and NOX2.
Keywords: biomarker, inflammasome, mitochondria, NAFLD, oxidative stress
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is currently the most
common liver disease in the world and the second most common
cause of liver transplantation in the United States (1, 2).
Our understanding of NAFLD pathogenesis and natural
history has greatly expanded in the last decade, however, many
issues remain unsolved. The liver plays a central role in regulating
lipid homeostasis through processes that are strictly regulated
by complex interactions between hormones, nuclear receptors,
and transcription factors-related pathways. Their alteration may
cause the retention of fat within the liver and the subsequent
development of NAFLD (3, 4).
Another important player in the onset of NAFLD and
its progression to non-alcoholic steatohepatitis (NASH) is
mitochondrial dysfunction (5) that can alter the balance
between prooxidants/antioxidants, leading to an increase of
non-metabolized free fatty acids (FFAs) in the cytosol and
the consequent induction of reactive oxygen species (ROS)
production. A “primary” mitochondrial dysfunction has been
proposed as one of the mechanisms of FFAs accumulation
in the hepatocytes of NAFLD patients (6), however, an
overload of FFAs into mitochondria may be able by itself
to lead to dissipation of the membrane potential, loss of
ATP synthesis capacity, and enhanced ROS generation (7).
In addition, the accumulation of lipotoxic intermediates
may promote inflammation and alter insulin signaling,
facilitating the establishment of an insulin resistance state
(5, 8).
Further topics of major interest regard the interference with
pathways associated to recognition receptors including Toll-
like receptors (TLRs) and NOD-like receptors (NLRs) (9),
and downstream signaling involving peroxisome proliferator
activating ligand receptors (PPAR), sterol regulatory element
binding protein 1c (SREBP-1c), nuclear factor kappa-light-chain
enhancer of activated B cells (NF-kB), and NADPH oxidase 2
(NOX2) (1, 10, 11).
In an “hormonocentric” view of NAFLD pathogenesis, all
these processes may be triggered by circulating factors (12), that
may represent diagnostic or prognostic biomarkers.
Based on these premises, we aimed to evaluate whether
factors circulating in the blood of NAFLD patients
may modulate one or more of the above-mentioned
processes. Hence, in the present study we examined the




Experiments were conducted between October 2018 and March
2019 using plasma from 12 NAFLD patients and 12 healthy
subjects. The use of excess plasma remaining from blood
samples taken for the routinary clinical monitoring of NAFLD
patients has been approved by the local Ethics Committee
(Ethical Committee of the “Azienda Ospedaliera Maggiore della
Carità” University Hospital in Novara). Patients and controls
have given written informed consent for experimental use of
pseudonymized clinical data and blood specimens. The work was
carried out in accordance with The Code of Ethics of the World
Medical Association (Declaration of Helsinki).
The clinical monitoring and plasma sampling of patients
and controls were performed at Liver Clinic Unit, “Azienda
Ospedaliera Maggiore della Carità” University Hospital
in Novara.
Culture of Huh7.5 Cells
The human hepatocellular carcinoma cell line Huh7.5 (Apath
L.L.C New York, USA) (13) was maintained in Dulbecco’s
modified Eagle’s medium (DMEM; Sigma, Milan, Italy)
supplemented with 10% fetal bovine plasma (FBS; Euroclone,
Pero, Milan, Italy), 2mM L-glutamine (Euroclone), 1%
penicillin-streptomycin (P/S; Euroclone), at 37◦C with 5% CO2
in incubator.
Isolation of Hepatocytes From Human
Liver Biopsy Specimens
From October 2018 until November 2019, 10 liver samples
(i.e., 50–100 g each) were obtained from patients undergoing
surgery at General Surgery Unit, Azienda Ospedaliera Maggiore
della Carità University Hospital, in Novara, due to primary or
metastatic liver resectable tumor.
The specimens were acquired from the non-neoplastic portion
of the liver parenchyma resected during the surgery. All tissue
donors gave written informed consent for experimental use of
pseudonymized clinical data and liver specimen prior to surgery.
Then fresh samples were transferred on ice cold physiologic
saline solution to Physiology laboratory, and hepatocytes were
immediately isolated, as previously performed (14, 15). Briefly,
liver specimens were minced with a scalpel and undergone
a two steps collagenase procedure; the cell pellet was, then,
centrifugated at 300 g for 5min and the cell pellet was filtered
through a nylon mesh. Thereafter, hepatocytes were pooled
Frontiers in Medicine | www.frontiersin.org 2 July 2021 | Volume 8 | Article 693997
Grossini et al. NAFLD Plasma Causes Hepatocytes Damage
and seeded into plates coated with collagen-I (Sigma), and
maintained in DMEM/HAM’S F-12 (Euroclone) supplemented
with 10% FBS (Euroclone), 100 U/ml penicillin (Sigma), 0.1
mg/ml streptomycin (Sigma), and 2mM L-glutamine (Sigma).
Finally, they were transferred into 75-cm2 culture flasks
(Euroclone) in incubator under standard conditions. The
culturing was performed until passage 15 (16).
Experimental Protocol
To evaluate the effects of plasma samples taken from NAFLD
patients and healthy subjects, on cell viability (MTT Assay),
mitochondrial membrane potential (JC-1 Assay), H2O2 release
(ROS-Glo H2O2,) mitochondrial ROS (mitoROS) release,
triglycerides content (Triglyceride assay) and protein expression
(Western Blot) in Huh7.5 cells/primary human hepatocytes, co-
culture experiments were performed, by using specific Transwell
inserts (Supplementary Figure 1A).
For the experiments, plasma samples from 12NAFLD patients
and 12 healthy subjects were plated in the apical compartment
of the insert and left to act for 3 h, while, Huh7.5 cells/primary
human hepatocytes were plated in the basal compartment.
The 3 h time limit for stimulation was chosen based on
preliminary time-course experiments during which Huh7.5 cells
were exposed to plasma for 3, 12, and 24 h, showing that cell
viability was drastically reduced already at 12 h. In addition,
preliminary experiments were performed on both Huh7.5 cells
and primary human hepatocytes with 5, 10, and 20% plasma
calculated in relation to the total volume of each insert. In those
experiments the effects of plasma from NAFLD patients and
healthy subjects on cell viability and H2O2 release were measured
(Supplementary Figure 1B). The results obtained allowed us
to select the proper plasma concentration to be used for all
next experiments performed on Huh7.5 cells. Furthermore,
in some experiments, 1 nM inflammasome NLRP3 inhibitor
(MCC950) was administrated to Huh7.5 cells for 30min alone
or before 200 pM TNFα (for 3 h) in co-stimulation with plasma.
Some samples of Huh7.5 cells and primary human hepatocytes
were not treated with plasma and were used as “control.”
At the end of stimulations, various assays were performed
(Supplementary Figure 1A). All experiments were conducted in
triplicate and repeated at least five times.
1) Cell Viability
Cell viability was examined in Huh7.5 cells and primary
human hepatocytes by using the 1% 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyl tetrazolium bromide (MTT; Life Technologies
Italia, Monza, Italy; catalog number CT02) dye, as previously
performed (17–21) and described in Supplementary Material.
Cell viability was determined by measuring the absorbance
through a spectrometer (VICTORTM X Multilabel Plate Reader;
PerkinElmer) with a wavelength of 570 nm and cell viability was
calculated by setting control cells as 100%.
Mitochondrial Membrane Potential
Measurement
Mitochondrial membrane potential measurement in Huh7.5
cells was performed with JC-1 assay (17, 19–22). The detailed
description of methods is reported in Supplementary Material.
The mitochondrial membrane potential was determined by
measuring the red (excitation 550 nm/emission 600 nm)
and green (excitation 485 nm/emission 535 nm) fluorescence
through a spectrometer (VICTORTM X Multilabel Plate Reader;
PerkinElmer). The data were normalized vs. control cells.
2) Mitochondrial ROS Quantification
MitoROS production was determined through the Cayman’s
Mitochondrial ROS Detection Assay Kit (Cayman Chemical;
catalog number 701600), as previously performed (23) and
described in Supplementary Material. TheMitoROS production
was measured with an excitation and emission wavelength of
480 and 560 nm, respectively, by using a spectrophotometer
(VICTORTM X Multilabel Plate Reader; PerkinElmer). The data
were normalized vs. control cells.
3) ROS-Glo H2O2 Quantification
H2O2 production was determined by the ROS-Glo H2O2 Assay,
following themanufacturer’s instructions (Promega Corporation;
Padova, Italy; catalog number G8820) (24, 25). The detailed
description of methods is reported in Supplementary Material.
The H2O2 production was quantified as relative luminescence
by using a spectrophotometer (VICTORTM X Multilabel Plate
Reader; PerkinElmer). The data were normalized vs. control cells.
4) Triglycerides Quantification
Triglycerides measurement was performed with a specific
kit (Cayman Chemical; catalog number 10010303) and as
described in Supplementary Material. The triglycerides
content was detected following the manufacturer’s instructions
through a spectrometer (VICTORTM X Multilabel Plate Reader;
PerkinElmer) at excitation/emission wavelengths of 530–550 nm
(22). The value of each sample was quantified in respect to
triglycerides standard curve and expressed as triglycerides
content (mg/dl).
5) Cell Lysates
For protein expression/activation, Huh7.5 cells were stimulated
as described for various assays. For the experiments, 400000
Huh7.5 cells/insert in 6-Transwell plate were plated. At
the end of stimulation, Huh7.5 cells were lysed in iced
Ripa buffer supplemented with sodium orthovanadate (2mM;
Sigma) and protease inhibitors cocktail (1mM; Thermo Fisher
Scientific) and phenylmethanesulfonyl fluoride (1mM; Sigma).
The extracted proteins were quantified through bicinchoninic
acid protein (BCA, Pierce) and used for electrophoresis and
immunoblotting studies (16–22). Due to shortage of plasma
specimens, experiments were conducted with plasma taken from
three NAFLD patients and three healthy subjects and were
repeated at least three times.
Western Blot Analysis
Cell lysates (30 µg protein each sample) were dissolved
in 5× Laemmli buffer, boiled for 5min and resolved in
10% sodium dodecyl sulfate polyacrylamide gel electrophoresis
gels (Bio-Rad Laboratories). After electrophoresis they were
transferred to polyvinylidene fluoride membranes (Bio-Rad
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Laboratories) and incubated overnight at 4◦C with specific
primary antibodies: anti Nf-kB (p-50; 1:1,000; Santa Cruz
Biotechnology, catalog number sc-8414), anti gp91-phox (NOX2;
1:1,000; Santa Cruz Biotechnology, catalog number sc-130543),
anti PPAR-γ (1:1,000; Santa Cruz Biotechnology, catalog number
sc-271392), anti SREBP-1c (1:1,000; Santa Cruz Biotechnology,
catalog number sc-13551). The membranes were washed and
then incubated with horseradish peroxidase-coupled goat anti-
rabbit IgG (Sigma), peroxidase-coupled rabbit anti-goat IgG and
horseradish peroxidase-coupled goat anti-mouse IgG (Sigma) for
45min and were developed through a non-radioactive method
using Western Lightning Chemiluminescence (PerkinElmer Life
and Analytical Sciences). Phosphorylated protein expression
was calculated as a ratio toward β-actin (1:5,000; Santa Cruz
Biotechnology; catalog number sc-47778) detection.
Statistical Analysis
Statistical analysis was performed using STATVIEW version 5.0.1
for Microsoft Windows (SAS Institute Inc., Cary NC, USA).
Data were checked for normality before statistical analysis. All
data are presented as means ± standard deviation (SD) of
five independent experiments for each experimental protocol.
Differences between groups were analyzed by one-way ANOVA
and Bonferroni post hoc tests. The threshold for statistical
significance was 0.05 (two-tails).
RESULTS
NAFLD patients were seven males and five females, aged 51± 14
years, had a body mass index (BMI) of 31.1 ± 4.0 kg/m2, plasma
alanine aminotransferase (ALT) concentration of 43 ± 29 U/L,
plasma total cholesterol of 182 ± 30.4 mg/dl, liver stiffness and a
controlled attenuation parameter measured by FibroScan R© of 7.1
± 1.9 kPa and 297± 45 dB/m, respectively. Healthy subjects were
sevenmales and five females, aged 24.2± 0.4 year, had a BMI 22.9
± 2.9 kg/m2, plasma ALT concentration of 23 ± 4 U/L, plasma
total cholesterol of 167± 19mg/dl, liver stiffness and a controlled
attenuation parameter measured by FibroScan R© of 5.4 ± 1 kPa
and 186 ± 27 dB/m, respectively. Significant differences were
observed in age, BMI, ALT, controlled attenuation parameter
and liver stiffness measured between NAFLD and non-NAFLD
patients (p < 0.05).
A dose response study was executed in order to choose
the proper plasma concentration for the in vitro experiments.
As shown in Supplementary Figure 2, plasma from NAFLD
patients was able to reduce cell viability and increase H2O2
release in both Huh7.5 cells and primary human hepatocytes. In
addition, a grading response was seen by using 5–20% plasma.
Indeed, as regarding primary human hepatocytes viability, it
amounted to 25, 34, and 43% about, in cells treated with 20,
10, and 5% NAFLD plasma, respectively. At the same time ROS
release increased nearly by 100, 76, and by 56%. Moving on
Huh7.5 cells, cell viability amounted to 34, 43, and 53% about,
in cells treated with 20, 10, and 5% NAFLD plasma, respectively,
whereas ROS release increased nearly by 80, 60, and 40%.
Although the highest effects were observed after the treatment
with the 20% plasma concentration, we decided to choose the
5% plasma concentration for all subsequent experiments in order
to save plasma. As described in Figure 1, in Huh7.5 cells,
plasma of NAFLD patients was able not only to reduce the cell
viability but also mitochondrial membrane potential, by 47.25 ±
13.2% and 23.5 ± 0.8%, respectively. The finding of a reduction
of mitochondrial membrane polarization would confirm the
harmful effects elicited by NAFLD plasma. It is to note that those
effects were accompanied by an increase not only of H2O2 release
amounting to 45 ± 1.3%, but also of mitoROS release of 20.2 ±
0.7%. In addition, an increase of triglycerides content of 27.8 ±
2.1% was observed, as well.
In the presence of MCC950, the NLRP3 inflammasome
inhibitor, the effects of NAFLD plasma on Huh7.5 cells were
counteracted. Hence, cell viability and mitochondrial membrane
potential were increased in comparison with findings obtained in
Huh7.5 cells treated with NAFLD plasma alone (Figures 1A,B).
Moreover, ROS andmitoROS release were reduced, as well as, the
triglycerides content (Figures 1C–E).
It is to note that all the effects of NAFLD plasma on Huh7.5
cells were higher than those caused by plasma from healthy
subjects (Figure 2). Also, TNFα was able to reduce cell viability,
mitochondrial membrane potential, to increase triglycerides
content and promote hydrogen peroxide and mitoROS release in
a stronger way in the presence of NAFLD plasma than healthy
subjects’ plasma. The NLRP3 inflammasome inhibitor, MCC950,
was so effective in preventing the deleterious effects of NAFLD
plasma that no differences could be observed between NAFLD
plasma and healthy subjects’ plasma, as regarding mitochondrial
membrane potential, triglycerides content and mitoROS release.
Western blot analysis performed on Huh7.5 cells treated with
NAFLD plasma at 5% concentration showed the involvement
inflammatory pathways and of an intracellular signaling related
to lipid accumulation in liver during NAFLD. Indeed, in Huh7.5
cells treated with plasma of NAFLD patients, an increase in
the expression of NF-kB, NOX2, PPARγ and SREBP-1c of 28.7
±14.8%, 31,8 ± 16,1%, 55 ± 13%, 34,7 ± 13%, respectively, was
observed (Figures 3, 4).
In our experiments we used TNFα as positive “inflammatory”
control to stimulate Huh7.5 cells treated with plasma of both
NAFLD patients and healthy subjects. As observed in previous
experiments, also in Western blot analysis all effects of plasma
of NAFLD patients were potentiated by TNFα and reduced by
MCC950 (Figures 1–4).
In addition, all the above effects observed in Huh7.5 cells
treated with plasma of NAFLD patients were accompanied by
an increase in the expression of NF-kB, NOX2, PPARγ and
SREBP-1c of 28.7 ±14.8%, 31,8 ± 16,1%, 55 ± 13%, 34,7 ±
13%, respectively (Figures 3, 4). All effects of plasma of NAFLD
patients were potentiated by TNFα and reduced by MCC950
(Figures 1–4).
DISCUSSION
The present paper documents that exposure of hepatocytes to
plasma from NAFLD patients was able to affect cell viability
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FIGURE 1 | Effects of NAFLD plasma on Huh7.5 cell viability (A), mitochondrial membrane potential (B), triglycerides content (C), H2O2 release (D) and mitochondrial
ROS (mitoROS, E). C=non-treated cells. MCC950 (NLRP3 inflammasome inhibitor, 1 nM for 30 min); TNFα (200 pM for 3 h). Reported data are means ± SD of five
independent experiments for each experimental protocol.
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FIGURE 2 | Comparison between the effects of NAFLD plasma and of plasma from healthy subjects on Huh7.5 cell viability (A), mitochondrial membrane potential
(B), triglycerides content (C), H2O2 release (D) and mitochondrial ROS (mitoROS, E). Abbreviations are as described in Figure 1. Reported data are means ± SD of
five independent experiments for each experimental protocol.
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FIGURE 3 | Effects of NAFLD plasma on NF-kB (A) and NOX2 (B) expression in Huh7.5 cells. P, patient; M, MCC950 (1 nM, for 30min). Other abbreviations are as
described in previous Figures. In the densitometric analysis, all values are normalized vs. control which is normalized, as well, and considered as 1. They are shown as
fold changes vs. control. Reported data are means ± SD of five independent experiments for each experimental protocol.
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FIGURE 4 | Effects of NAFLD plasma on PPARγ (A) and SREBP-1c (B) expression in Huh7.5 cells. P, patient; M, MCC950 (1 nM, for 30min). Other abbreviations are
as described in previous Figures. In the densitometric analysis, all values are normalized vs. control which is normalized, as well, and considered as 1. They are shown
as fold changes vs. control. Reported data are means ± SD of five independent experiments for each experimental protocol.
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and to modulate intracellular pathways in vitro in the direction
predicted by current hypotheses on NAFLD pathogenesis.
In recent years, several in vitromodel of NAFLD of increasing
complexity have been proposed, from culture of a single cell
type to 3D cocultures and body-on-a-chip systems (26). Human
hepatoma cell lines are easy to maintain and may be apt
for multiparametric evaluation of steatosis (27), though their
enzymatic profile may differ significantly from that of normal
hepatocytes. On these premises, we decided to set a system
in which human hepatoma cells could be maintained at ease
varying conditions in which they were grown by using specific
stimulant and inhibitor molecules. It should be of particular
interest and represent a touch of originality the use of plasma
for treating hepatocytes, Hence, almost all previous studies have
been performed by simulating an in vitro condition of NAFLD
milieu, usingmixed FFAs solutions. Here, we aimed to examining
the role of any circulating factors playing a pathophysiological
role in the onset of NAFLD. The Huh7.5 cell line that we
employed in our experiments has gained popularity for being
highly permissive for hepatitis C virus replication in vitro (28).
Moreover, some experiments have been performed in human
primary hepatocytes, as well, to set up the optimal experimental
conditions and to confirm the results obtained in Huh7.5 cells.
It is to note that the method employed for hepatocytes
isolation is the one that was reported to result in hepatocytes
populations of high purity with retained physiological activity in
vitro (14).
In both Huh7.5 cells and human primary hepatocytes we
tested 5, 10, and 20% NAFLD and non-NAFLD plasma samples
on cell viability and H2O2 release, so that we could select the
proper plasma concentration to be used in all other experiments
performed on Huh7.5 cells only. To culture medium of Huh7.5
cells we also added TNFα, to reproduce in vitro conditions
mimicking the steatohepatitis milieu (29), where TNFα plays a
major role (30).
Furthermore, experiments were conducted in the presence
or absence of the potent and selective inhibitor MCC950,
which targets directly the NLRP3 ATP-hydrolysis motif for
inflammasome inhibition (31).
Regarding the loss of cell viability that we observed after
exposure to NAFLD plasma, it was presumably due to the
differences in triglycerides content and oxidants release observed
in Huh7.5 cells. It is to note that H2O2 and mitoROS have widely
been considered as main contributors to liver injury and disease
progression in NAFLD (32–35).
These effects were amplified in the presence of TNFα and
reduced by the pretreatment with MCC950. It is noteworthy
that in similar in vitro models, TNFα appears to mediate an
increase of mitochondrial Ca2+ leading to production of ATP
and ROS, with the shedding of TNF receptor 1 (which acts as
a decoy) limiting the propagation of the inflammatory response
(36). Our results would indicate the potentiation by TNFα of the
harmful effects elicited by not yet clarified “inflammatory” factors
circulating in the plasma of NAFLD patients, a mechanism that
was counteracted by the NLRP3 inflammasome inhibition.
Following the “multiple-hit” hypothesis, hepatic lipid
overload would induce the overproduction of oxidants that
could be detrimental for DNA, lipids and proteins and lead to
the accumulation of the so called “damage-associated molecular
pattern” (DAMPS), which would induce liver injury. In addition,
the impairment of the electrons transfer chain and the fall of
mitochondrial membrane potential could be followed by cell
death (35).
Mitochondrial membrane potential is essential for cells,
enabling them to store energy: a long-lasting drop of
mitochondrial potential is deleterious to cell viability, possibly
more because of interference by products of ATP hydrolysis than
by ATP in itself. About this issue it is to note that the increased
mitoROS release we have observed was accompanied by the fall
of mitochondrial membrane potential in Huh7.5 cells.
Interestingly, we also found an increase of SREBP-1c and
PPARγ expression, which are involved in the intracellular
triglycerides accumulation (1) and an increase of NF-kB and
NOX2. As concerning SREBP-1c, it has been found to be
involved in mitochondrial oxidants release through AQP8
upregulation (36). NF-kB is responsible for the transcription of
pro-inflammatory molecules; among other stimuli like SREBP-
1c (37). Also, NOX enzymes, especially NOX1, NOX2, and
NOX4, have been associated with liver injuries in NAFLD both
in vivo and in vitro, through the increased ROS release and
the reciprocal interaction between different NOX enzymes and
mitochondria (38).
The data we have obtained with MCC950 highlight the
involvement of NLRP3 inflammasome in eliciting the harmful
effects of NAFLD plasma in Huh7.5 cells. Our findings are in
agreement with previous observations about the role of NOD-like
receptors in NAFLD pathogenesis. In fact, the release by dying
hepatocytes of DAMPS can be detected by members of NOD-
like receptors, such as the NLRP3 inflammasome. Its activation
is followed by cleavage of pro-caspase-1 into active caspase-1,
which, in turn, cleaves pro-IL-1β into mature IL-1β (39, 40).
Overall, the activation of NLRP3 inflammasomemay potentiate a
proinflammatory condition, resulting into stellate cells activation
and transformation in a myofibroblastic phenotype. The fact
however, that the only some effects of NAFLD plasma were
abolished by MCC950, whereas others were just reduced, would
suggest, on the one side, the important role played by NLRP3
inflammasome, and on the other side, the existence of other
mechanisms which could trigger the damage. As also previously
reported and confirmed by our results, intracellular pathways
related to SREBP-1c and PPARγ could be involved. In addition,
the modulation of inflammatory/anti-inflammatory cytokines,
like interleukin 6 or adiponectin, could play a role and could be
object of future studies.
Interestingly, the present data suggest the existence of an
association between the activation of the NLRP3 inflammasome
and that of intracellular pathways associated with SREBP-1c,
PPARγ, NOX2 and NF-kB. In the presence of the inhibitor
MCC950, the expression of all the above proteins was reduced
in Huh7.5 cells exposed to NAFLD plasma. Data about SREBP-
1c are also in agreement with previous findings in HepRG cells
(41). Thus, it could be hypothesized a role for the NLRP3
inflammasome in the regulation of triglycerides accumulation
via involvement of SREBP-1c and PPARγ, and in the onset
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of oxidative stress. Concomitantly or alternatively, the NLRP3
inflammasome may be responsible for oxidants release through
signaling involving NOX2 and NF-kB. Future studies could be
organized aimed at the analysis of other intracellular pathways
related to all the above pathways and their relationships. In
this context, it would be of interest to examine the role of
AMP-activated protein kinase (AMPK), which is crucial for the
regulation of fat mebabolism in liver.
One limitation of the present study is that NAFLD patients
and healthy subjects were different as regarding BMI and age.
This bias is somewhat inevitable, since NAFLD and NAFLD
progression are strongly related to BMI and age. Moreover,
sample size could be increased. The hepatoma cell line we
used is not fully comparable to those of normal hepatocytes,
though preliminary experiments performed on primary human
hepatocytes (data not shown) confirmed the results obtained
regarding cell viability and oxidant release. One may also argue
that the model does not allow the identification of any specific
pathogenic factor(s) and/or of putative biomarker(s); on the
other hand, it has the advantage of being free of bias on the
kind of substances involved. As said, our aim was to examine
the role of any circulating factor possibly involved in the onset
of NAFLD without venturing in the attempt of identifying all
possibleculprits. Indeed, this is the first study performed by using
NAFLD plasma on Huh7.5 cells and aimed at the analysis of
cell viability, mitochondrial function and oxidants release. In
addition, the role of main pathways involved in NAFLD onset
has been investigated by performing experiments in the presence
of an inhibitor and through Western Blot. The findings of
harmful effects elicited by NAFLD plasma on hepatocytes would
represent the starting point for the execution of future studies
aimed at deepening the aforementioned issues. In particular, the
application of proteomic andmetabolomic profiling technologies
to NAFLD plasma might contribute to identify any circulating
factor(s) (microRNA, extracellular vesicles), whereas, in vitro
experiments could be organized to increase the knowledge about
the intracellular mechanisms (SREBP-1c, PPARγ, inflammasome
molecules, AMPK).
CONCLUSIONS
In summary, we have established an in vitro model in which
exposure to NAFLD plasma, in agreement with what predicted
by “hormonocentric” theories on NAFLD pathogenesis (12, 42)
resulted in loss of cell viability and activation of pathways known
to be involved in inflammation and tissue damage. Substances
present inNAFLDplasma could have affected lipidmetabolism of
Huh7.5 cells: triglycerides accumulation activated as downstream
signaling involving SREBP-1c and PPARγ may have acted as a
starting point. Hence, accumulation of triglycerides may have
hampered mitochondrial function either directly or through
increased oxidants release, NOX2 and NLRP3 inflammasome-
related pathways.
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